GlassScriptPhysician profile
Paul Guichard
NPI 1649269796
$260,407.84
in general payments reported to CMS, 2019-2025
40 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $17K · 2021: $15K · 2022: $30K · 2023: $36K · 2024: $48K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $13K · Food and Beverage: $13K · Consulting Fee: $5,550 · Education: $28.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,947.50 |
| Travel and Lodging | $12,920.88 |
| Food and Beverage | $12,686.64 |
| Consulting Fee | $5,550.00 |
| Education | $28.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $105,171.60 | 2019-2025 | Tyvaso, Remodulin, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $83,932.04 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $31,214.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $30,010.18 | 2023-2025 | Winrevair, Verquvo |
| Penumbra, INC. | $3,166.81 | 2023-2025 | Indigo System, Penumbra System |
| Inari Medical, INC. | $1,144.26 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $702.94 | 2019-2024 | Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $690.17 | 2019-2025 | |
| Pfizer INC. | $499.76 | 2021-2025 | |
| Edwards Lifesciences Corporation | $496.27 | 2019-2025 | |
| Abiomed | $405.72 | 2019-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $390.36 | 2019-2025 | Lifevest |
| Medtronic, INC. | $377.64 | 2021-2024 | Symplicity G3, Onyx Frontier |
| Angiodynamics, INC. | $376.01 | 2021-2025 | Alphavac, Angiovac |
| Astrazeneca Pharmaceuticals LP | $300.95 | 2019-2025 | Wainua, Onglyza, Brilinta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| W. L. Gore & Associates, INC. | $150.10 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.94 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $121.51 | 2019-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $119.82 | 2021-2025 | |
| Abbott Laboratories | $115.35 | 2023-2025 | Xience Skypoint, Cardiomems |
| Amgen INC. | $111.09 | 2019-2025 | Repatha |
| Imperative Care, INC | $95.48 | 2025 | Symphony Catheter |
| Janssen Pharmaceuticals, INC | $72.60 | 2019-2023 | Xarelto |
| Sandoz INC. | $59.24 | 2023-2025 | Treprostinil |
| Medtronic Vascular, INC. | $54.09 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $39.04 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $33.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.95 | 2019 | |
| Scpharmaceuticals INC. | $30.10 | 2024 | |
| Stryker Corporation | $29.13 | 2025 | Artix Mt |
| Glaxosmithkline, LLC. | $27.16 | 2025 | |
| Lantheus Medical Imaging, INC. | $26.94 | 2021 | |
| Impulse Dynamics (USA) INC. | $26.30 | 2022 | |
| Cardiva Medical, INC. | $23.42 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Philips North America LLC | $19.30 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.59 | 2023 | Onpattro |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Guichard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.